Gerlinde Layh-Schmitt1, Robert A Colbert. 1. William S. Rowe Division of Rheumatology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center and Cincinnati Children's Research Foundation, Cincinnati, Ohio, USA.
Abstract
PURPOSE OF REVIEW: To inform readers of recent advances in our understanding of the development and function of Th17 T cells and emerging data suggesting that the interleukin-23/interleukin-17 axis may be involved in the pathogenesis of spondyloarthritis. RECENT FINDINGS: The discovery of CD4+ Th17 T cells and the interleukin-23/interleukin-17 axis has challenged existing paradigms and the role of Th1 T cells in many autoimmune diseases. The development and cytokine profile of Th17 T cells differs in mice and humans. In humans, interleukin-23 synergizes with interleukin-6 and interleukin-1 to promote Th17 development. In mice, transforming growth factor-beta and interleukin-6 are critical, whereas interleukin-23 is more important at later stages promoting interleukin-17 production. In mice, CD4+ cells producing interferon-gamma appear to be distinct from interleukin-17-producing cells, while in humans cells secreting both cytokines have been observed. Growing evidence from animal models, cytokine analyses of patient fluids, and whole-genome association studies suggest that the interleukin-23/interleukin-17 axis plays an important role in spondyloarthritis pathogenesis. Possible links between an HLA-B27-induced unfolded protein response and activation of the interleukin-23/interleukin-17 axis have been observed in animal models and may contribute to the development of the spondyloarthritis phenotype. SUMMARY: Activation of the interleukin-23/interleukin-17 axis in spondyloarthritis has important therapeutic implications.
PURPOSE OF REVIEW: To inform readers of recent advances in our understanding of the development and function of Th17 T cells and emerging data suggesting that the interleukin-23/interleukin-17 axis may be involved in the pathogenesis of spondyloarthritis. RECENT FINDINGS: The discovery of CD4+ Th17 T cells and the interleukin-23/interleukin-17 axis has challenged existing paradigms and the role of Th1 T cells in many autoimmune diseases. The development and cytokine profile of Th17 T cells differs in mice and humans. In humans, interleukin-23 synergizes with interleukin-6 and interleukin-1 to promote Th17 development. In mice, transforming growth factor-beta and interleukin-6 are critical, whereas interleukin-23 is more important at later stages promoting interleukin-17 production. In mice, CD4+ cells producing interferon-gamma appear to be distinct from interleukin-17-producing cells, while in humans cells secreting both cytokines have been observed. Growing evidence from animal models, cytokine analyses of patient fluids, and whole-genome association studies suggest that the interleukin-23/interleukin-17 axis plays an important role in spondyloarthritis pathogenesis. Possible links between an HLA-B27-induced unfolded protein response and activation of the interleukin-23/interleukin-17 axis have been observed in animal models and may contribute to the development of the spondyloarthritis phenotype. SUMMARY: Activation of the interleukin-23/interleukin-17 axis in spondyloarthritis has important therapeutic implications.
Authors: Marla C Dubinsky; Dai Wang; Yoana Picornell; Iwona Wrobel; Lirona Katzir; Antonio Quiros; Debra Dutridge; Ghassan Wahbeh; Gary Silber; Ron Bahar; Emebet Mengesha; Stephan R Targan; Kent D Taylor; Jerome I Rotter Journal: Inflamm Bowel Dis Date: 2007-05 Impact factor: 5.325
Authors: Mark Tremelling; Fraser Cummings; Sheila A Fisher; John Mansfield; Rhian Gwilliam; Andrew Keniry; Elaine R Nimmo; Hazel Drummond; Clive M Onnie; Natalie J Prescott; Jeremy Sanderson; Francesca Bredin; Carlo Berzuini; Alastair Forbes; Cathryn M Lewis; Lon Cardon; Panos Deloukas; Derek Jewell; Christopher G Mathew; Miles Parkes; Jack Satsangi Journal: Gastroenterology Date: 2007-02-24 Impact factor: 22.682
Authors: Robert A Colbert; Atul A Deodhar; David Fox; Ellen M Gravallese; Muhammad Asim Khan; Dennis McGonagle; John D Reveille; Georg Schett; Michael Weisman; Daniel O Clegg Journal: J Rheumatol Date: 2009-07 Impact factor: 4.666